SFZN Stock Overview
Provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 1,132.00 |
| 52 Week High | CHF 1,136.00 |
| 52 Week Low | CHF 655.00 |
| Beta | 0.71 |
| 11 Month Change | 14.23% |
| 3 Month Change | 22.78% |
| 1 Year Change | 42.30% |
| 33 Year Change | 29.89% |
| 5 Year Change | 175.76% |
| Change since IPO | 1,389.47% |
Recent News & Updates
A Look At The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)
Aug 04
Siegfried Holding AG (VTX:SFZN) Not Flying Under The Radar
Jun 17Recent updates
A Look At The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)
Aug 04Siegfried Holding AG (VTX:SFZN) Not Flying Under The Radar
Jun 17Siegfried Holding AG's (VTX:SFZN) CEO Compensation Looks Acceptable To Us And Here's Why
Apr 12Does Siegfried Holding (VTX:SFZN) Have A Healthy Balance Sheet?
Mar 15Earnings Miss: Siegfried Holding AG Missed EPS By 18% And Analysts Are Revising Their Forecasts
Feb 23Siegfried Holding AG's (VTX:SFZN) Business Is Yet to Catch Up With Its Share Price
Jan 27Is Siegfried Holding AG (VTX:SFZN) Worth CHF840 Based On Its Intrinsic Value?
Jan 07Is Now The Time To Put Siegfried Holding (VTX:SFZN) On Your Watchlist?
Dec 02We Think Siegfried Holding (VTX:SFZN) Can Stay On Top Of Its Debt
Nov 13A Look At The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)
Sep 28Here's Why We Think Siegfried Holding (VTX:SFZN) Might Deserve Your Attention Today
Aug 16With EPS Growth And More, Siegfried Holding (VTX:SFZN) Makes An Interesting Case
May 13Is Siegfried Holding (VTX:SFZN) Using Too Much Debt?
Apr 25With EPS Growth And More, Siegfried Holding (VTX:SFZN) Makes An Interesting Case
Jan 20Is Siegfried Holding (VTX:SFZN) A Risky Investment?
Dec 28Here's Why Siegfried Holding (VTX:SFZN) Has Caught The Eye Of Investors
Oct 13Siegfried Holding (VTX:SFZN) Has A Pretty Healthy Balance Sheet
Sep 25Should You Be Adding Siegfried Holding (VTX:SFZN) To Your Watchlist Today?
Jun 24Siegfried Holding (VTX:SFZN) Seems To Use Debt Quite Sensibly
Apr 08Do Siegfried Holding's (VTX:SFZN) Earnings Warrant Your Attention?
Mar 21Does Siegfried Holding (VTX:SFZN) Have A Healthy Balance Sheet?
Dec 23Should You Be Adding Siegfried Holding (VTX:SFZN) To Your Watchlist Today?
Dec 05Here's Why Siegfried Holding (VTX:SFZN) Can Manage Its Debt Responsibly
Sep 19If You Like EPS Growth Then Check Out Siegfried Holding (VTX:SFZN) Before It's Too Late
Sep 01These 4 Measures Indicate That Siegfried Holding (VTX:SFZN) Is Using Debt Reasonably Well
Jun 11Here's Why We Think Siegfried Holding (VTX:SFZN) Is Well Worth Watching
May 25Is Siegfried Holding (VTX:SFZN) A Risky Investment?
Mar 03Shareholders Are Thrilled That The Siegfried Holding (VTX:SFZN) Share Price Increased 227%
Jan 18Do Fundamentals Have Any Role To Play In Driving Siegfried Holding AG's (VTX:SFZN) Stock Up Recently?
Dec 22
What Kind Of Shareholders Hold The Majority In Siegfried Holding AG's (VTX:SFZN) Shares?
Nov 25Shareholder Returns
| SFZN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 2.2% | -1.1% | -3.4% |
| 1Y | 42.3% | 10.4% | 5.8% |
Return vs Industry: SFZN exceeded the Swiss Life Sciences industry which returned 8.8% over the past year.
Return vs Market: SFZN exceeded the Swiss Market which returned 5.1% over the past year.
Price Volatility
| SFZN volatility | |
|---|---|
| SFZN Average Weekly Movement | 3.3% |
| Life Sciences Industry Average Movement | 4.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.2% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: SFZN has not had significant price volatility in the past 3 months.
Volatility Over Time: SFZN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,797 | Reto Suter | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products.
Siegfried Holding AG Fundamentals Summary
| SFZN fundamental statistics | |
|---|---|
| Market cap | CHF 4.86b |
| Earnings (TTM) | CHF 128.86m |
| Revenue (TTM) | CHF 1.28b |
37.7x
P/E Ratio3.8x
P/S RatioIs SFZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFZN income statement (TTM) | |
|---|---|
| Revenue | CHF 1.28b |
| Cost of Revenue | CHF 952.10m |
| Gross Profit | CHF 332.25m |
| Other Expenses | CHF 203.38m |
| Earnings | CHF 128.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | 30.04 |
| Gross Margin | 25.87% |
| Net Profit Margin | 10.03% |
| Debt/Equity Ratio | 47.4% |
How did SFZN perform over the long term?
See historical performance and comparison